Edwards Lifesciences (NYSE:EW) Upgraded at Evercore ISI

Key Points

• Edwards Lifesciences has been upgraded to a strong-buy rating by Evercore ISI, with a price target increase from $80 to $88, indicating a potential upside of 14.74% from its current price.
• Recent quarterly earnings showed a 11.9% year-over-year revenue growth, reporting $1.53 billion against expectations of $1.49 billion and an EPS of $0.67.
• Insiders, including VP Daniel J. Lippis, have recently sold shares, indicating potential changes in their investment positions, as 0.34% of the stock is now owned by company insiders.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by research analysts at Evercore ISI from an "in-line" rating to an "outperform" rating in a research note issued on Tuesday, MarketBeat Ratings reports. The firm currently has a $88.00 target price on the medical research company's stock, up from their previous target price of $80.00. Evercore ISI's price target would indicate a potential upside of 14.74% from the company's previous close.

A number of other equities analysts have also commented on EW. Robert W. Baird raised their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Mizuho boosted their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Wall Street Zen cut shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 29th. Finally, Barclays raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 25th. Four research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $87.06.

Edwards Lifesciences Stock Up 0.2%

EW stock opened at $76.70 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market capitalization of $45.03 billion, a price-to-earnings ratio of 11.04, a PEG ratio of 3.68 and a beta of 1.05. The business's fifty day moving average price is $78.39 and its two-hundred day moving average price is $76.05. Edwards Lifesciences has a fifty-two week low of $64.51 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the company posted $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its stake in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after buying an additional 145 shares during the last quarter. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $1,760,000. Czech National Bank boosted its position in shares of Edwards Lifesciences by 5.8% during the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock valued at $11,214,000 after purchasing an additional 7,917 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its position in shares of Edwards Lifesciences by 2.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock valued at $1,124,000 after purchasing an additional 370 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Edwards Lifesciences by 13.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock valued at $5,582,000 after purchasing an additional 9,188 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.